GÃ¼nther Hochhaus

List of Publications by Year
in descending order

147 papers	4,160 citations	109321 35 h-index	144013 57 g-index
154 all docs	154 docs citations	154 times ranked	3370 citing authors

#	Article	IF	Citations
1	Pharmacokinetic aspects of biotechnology products. Journal of Pharmaceutical Sciences, 2004, 93, 2184-2204.	3.3	268
2	Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Current Medical Research and Opinion, 2003, 19, 491-499.	1.9	177
3	Receptorâ€Based Pharmacokineticâ€Pharmacodynamic Analysis of Corticosteroids. Journal of Clinical Pharmacology, 1993, 33, 115-123.	2.0	120
4	In Vitro and in Vivo Anti-Inflammatory Activity of the New Glucocorticoid Ciclesonide. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 249-258.	2.5	102
5	Pharmacokinetics of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. Journal of Clinical Pharmacology, 1995, 35, 302-305.	2.0	100
6	How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids. Proceedings of the American Thoracic Society, 2004, 1, 356-363.	3.5	98
7	Pharmacokinetic/Pharmacodynamic Aspects of Aerosol Therapy using Glucocorticoids as a Model. Journal of Clinical Pharmacology, 1997, 37, 881-892.	2.0	96
8	Population Pharmacokinetics and Pharmacodynamics of Ciclesonide. Journal of Clinical Pharmacology, 2003, 43, 365-378.	2.0	96
9	Comparative Pharmacology, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Inhaled Glucocorticosteroids. Immunology and Allergy Clinics of North America, 2005, 25, 469-488.	1.9	94
10	Soft drugsâ€”10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate. Journal of Steroid Biochemistry and Molecular Biology, 1991, 38, 149-154.	2.5	93
11	Pharmacokinetics of the Dietary Supplement Creatine. Clinical Pharmacokinetics, 2003, 42, 557-574.	3.5	93
12	Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 1-29.	1.4	93
13	Budesonide in previously untreated autoimmune hepatitis. Liver International, 2005, 25, 927-934.	3.9	86
14	Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD. AAPS Open, 2016, 2, .	1.3	73
15	Slow Release Formulations of Inhaled Rifampin. AAPS Journal, 2008, 10, 342-348.	4.4	70
16	Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. European Journal of Clinical Pharmacology, 1998, 53, 459-467.	1.9	65
17	Clinical Pharmacology of Pancreatic Enzymes in Patients with Cystic Fibrosis and In Vitro Performance of Microencapsulated Formulations. Journal of Clinical Pharmacology, 1994, 34, 158-166.	2.0	59
18	Methods used to assess pulmonary deposition and absorption of drugs. Drug Discovery Today, 2001, 6, 367-375.	6.4	58

#	Article	IF	Citations
19	Evaluation of the Transwell System for Characterization of Dissolution Behavior of Inhalation Drugs: Effects of Membrane and Surfactant. Molecular Pharmaceutics, 2015, 12, 2618-2624.	4.6	58
20	Pharmacokinetics of Methylprednisolone and Prednisolone After Single and Multiple Oral Administration. Journal of Clinical Pharmacology, 1997, 37, 916-925.	2.0	55
21	Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: Potential effects on clinical safety and efficacy. Clinical Therapeutics, 2008, 30, 1-13.	2.5	54
22	Equivalence Considerations for Orally Inhaled Products for Local Actionâ€"ISAM/IPAC-RS European Workshop Report. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, 117-139.	1.4	54
23	Drugs used in the treatment of opioid tolerance and physical dependence: a review. International Journal of Clinical Pharmacology and Therapeutics, 2004, 42, 191-203.	0.6	54
24	Kinetic modeling of plasmid DNA degradation in rat plasma. AAPS PharmSci, 1999, 1, 15-20.	1.3	53
25	A Pharmacokinetic Simulation Tool for Inhaled Corticosteroids. AAPS Journal, 2013, 15, 159-171.	4.4	53
26	Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. Journal of Clinical Pharmacology, 1995, 35, 1187-1193.	2.0	51
27	HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. Journal of Pharmaceutical and Biomedical Analysis, 1986, 4, 197-206.	2.8	50
28	Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. British Journal of Clinical Pharmacology, 2006, 62, 412-419.	2.4	50
29	Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharmaceutical Research, 1995, 12, 1096-1100.	3.5	48
30	Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert Opinion on Drug Delivery, 2005, 2, 519-532.	5.0	41
31	Pharmacokinetics and Pharmacodynamics of Dexamethasone Sodium-m-Sulfobenzoate (DS) after Intravenous and Intramuscular Administration: A Comparison with Dexamethasone Phosphate (DP). Journal of Clinical Pharmacology, 2001, 41, 425-434.	2.0	39
32	Single- and Multiple-Dose Pharmacokinetics of Oral Creatine. Journal of Clinical Pharmacology, 2003, 43, 29-37.	2.0	39
33	New Developments in Corticosteroids. Proceedings of the American Thoracic Society, 2004, 1, 269-274.	3.5	39
34	Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives. Therapeutic Delivery, 2013, 4, 343-367.	2.2	39
35	Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs. Journal of Pharmaceutical Sciences, 1992, 81, 1210-1215.	3.3	38
36	Chronic blockade of hindbrain glucocorticoid receptors reduces blood pressure responses to novel stress and attenuates adaptation to repeated stress. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2009, 296, R1445-R1454.	1.8	38

#	Article	IF	Citations
37	A sensitive LCâ€“MS/MS method for the quantification of fluticasone propionate in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2000, 22, 123-129.	2.8	36
38	Receptor binding studies of soft anticholinergic agents. AAPS PharmSci, 2001, 3, 44-56.	1.3	36
39	Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers. Pharmaceutical Research, 2017, 34, 2541-2556.	3.5	36
40	Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. European Respiratory Journal, 2006, 27, 511-516.	6.7	35
41	Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharmaceutical Research, 1998, 15, 461-465.	3.5	34
42	Single-Dose and Steady-State Pharmacokinetic and Pharmacodynamic Evaluation of Therapeutically Clinically Equivalent Doses of Inhaled Fluticasone Propionate and Budesonide, Given as DiskusÂ® or TurbohalerÂ® Dry-Powder Inhalers to Healthy Subjects. Journal of Clinical Pharmacology, 2001, 41, 1329-1338.	2.0	34
43	Pharmacokinetics of plasmid DNA in the rat. Pharmaceutical Research, 2001, 18, 67-74.	3.5	33
44	Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharmaceutical Research, 1996, 13, 1699-1703.	3.5	32
45	Dependency of Cortisol Suppression on the Administration Time of Inhaled Corticosteroids. Journal of Clinical Pharmacology, 1997, 37, 704-710.	2.0	30
46	Metabolism of dynorphin A 1-13 in human blood and plasma. Pharmaceutical Research, 1995, 12, 1165-1170.	3.5	29
47	Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats. Pharmaceutical Research, 1995, 12, 134-137.	3.5	29
48	Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. British Journal of Clinical Pharmacology, 2007, 64, 439-444.	2.4	29
49	Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 235-238.	1.4	27
50	Affinities of glucocorticoids for glucocorticoid receptors in the human lung. Agents and Actions, 1986, 17, 290-291.	0.7	26
51	Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharmaceutical Research, 1992, 09, 291-297.	3.5	26
52	Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Flunisolide after Inhalation. Journal of Clinical Pharmacology, 1997, 37, 893-903.	2.0	24
53	Delta opioid receptor in human neuroblastoma cell lines. Brain Research, 1986, 382, 327-331.	2.2	23
54	Simultaneous quantification of budesonide and its two metabolites, 6?-hydroxybudesonide and 16?-hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry. Biomedical Chromatography, 2003, 17, 158-164.	1.7	23

#	Article	IF	Citations
55	METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES. Drug Metabolism and Disposition, 2006, 34, 225-233.	3.3	23
56	Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century. Journal of Clinical Pharmacology, 2000, 40, 908-917.	2.0	20
57	Validation of a simple liquid chromatography assay for creatine suitable for pharmacokinetic applications, determination of plasma protein binding and verification of percent labeled claim of various creatine products. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 794, 157-165.	2.3	20
58	CONTRARY TO ADULT, NEONATAL RATS SHOW PRONOUNCED BRAIN UPTAKE OF CORTICOSTEROIDS. Drug Metabolism and Disposition, 2006, 34, 939-942.	3.3	20
59	Population Pharmacokinetic Modeling of the Unbound Levofloxacin Concentrations in Rat Plasma and Prostate Tissue Measured by Microdialysis. Antimicrobial Agents and Chemotherapy, 2014, 58, 678-686.	3.2	20
60	Nonpeptide Somatostatin Receptor Agonists Specifically Target Ocular Neovascularization via the Somatostatin Type 2 Receptor. , 2008, 49, 5094.		18
61	A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. Journal of Pharmacokinetics and Pharmacodynamics, 1999, 27, 127-147.	0.6	17
62	Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: Effect of different routes of administration. AAPS Journal, 2004, 6, 68-73.	4.4	17
63	Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. British Journal of Clinical Pharmacology, 2007, 64, 698-705.	2.4	17
64	Brain permeability of inhaled corticosteroids. Journal of Pharmacy and Pharmacology, 2010, 57, 1159-1167.	2.4	17
65	A Stability Analysis of a Modified Version of the Chi-Square Ratio Statistic: Implications for Equivalence Testing of Aerodynamic Particle Size Distribution. AAPS Journal, 2013, 15, 1-9.	4.4	17
66	Pharmacokinetics of intravenous dynorphin A(1â€“13) in opioid-naive and opioid-treated human volunteers*. Clinical Pharmacology and Therapeutics, 1998, 64, 27-38.	4.7	16
67	Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask. Journal of Pediatrics, 2006, 149, 793-797.	1.8	16
68	Pharmacokinetics and Pharmacodynamics of Inhaled Glucocorticoids. Journal of Asthma, 2008, 45, 13-24.	1.7	16
69	Budesonide and Ciclesonide: Effect of Tissue Binding on Pulmonary Receptor Binding. Drug Metabolism and Disposition, 2009, 37, 1421-1426.	3.3	16
70	Cholestenoic acid, an endogenous cholesterol metabolite, is a potent Î³-secretase modulator. Molecular Neurodegeneration, 2015, 10, 29.	10.8	16
71	Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents and Actions, 1990, 30, 377-380.	0.7	15
72	cAMP accumulation in opioid-sensitive SH-SY5Y neuroblastoma cells is modified by estradiol and progesterone. Molecular and Cellular Endocrinology, 1991, 78, 155-162.	3.2	15

#	Article	IF	Citations
73	An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. AAPS PharmSci, 2000, 2, 28-37.	1.3	15
74	A sensitive liquid chromatographyâ€“tandem mass spectrometry method for the quantification of mometasone furoate in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 175-179.	2.3	15
75	Evaluation of the Administration Time Effect on the Cumulative Cortisol Suppression and Cumulative Lymphocytes Suppression for Onceâ€Daily Inhaled Corticosteroids: A Population Modeling/Simulation Approach. Journal of Clinical Pharmacology, 2008, 48, 1069-1080.	2.0	15
76	Pharmacokinetic/Pharmacodynamic Modeling of Total Lymphocytes and Selected Subtypes After Oral Budesonide. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 441-459.	1.8	14
77	Identification of glucocorticoid receptors in normal and neoplastic adult human lung. Research in Experimental Medicine, 1983, 182, 71-78.	0.7	13
78	Pharmacokinetics and Rectal Bioavailability of Hydrocortisone Acetate after Single and Multiple Administration in Healthy Subjects and Patients. Journal of Clinical Pharmacology, 2001, 41, 536-541.	2.0	13
79	Differences in Inhaled Fluticasone Bioavailability Between Holding Chambers in Children with Asthma. Pharmacotherapy, 2002, 22, 947-953.	2.6	13
80	Development of a placebo effect model combined with a dropout model for bipolar disorder. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 359-368.	1.8	13
81	A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach. AAPS Journal, 2015, 17, 999-1010.	4.4	13
82	Characterization of a dextran-budesonide prodrug for inhalation therapy. European Journal of Pharmaceutical Sciences, 2019, 129, 58-67.	4.0	13
83	Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?. AAPS Journal, 2021, 23, 48.	4.4	13
84	iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System. Molecular Pharmaceutics, 2022, 19, 2032-2039.	4.6	13
85	Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma. Journal of Pharmaceutical and Biomedical Analysis, 1985, 3, 566-573.	2.8	12
86	A selective HPLC/RIA for the determination of budesonide. Journal of Pharmaceutical and Biomedical Analysis, 1998, 17, 1235-1242.	2.8	12
87	In vitro deposition of fluticasone aerosol from a metered-dose inhaler with and without two common valved holding chambers. Annals of Allergy, Asthma and Immunology, 2002, 88, 204-208.	1.0	12
88	In Vitro Performance of Two Common Valved Holding Chambers with a Chlorofluorocarbon-Free Beclomethasone Metered-Dose Inhaler. Pharmacotherapy, 2003, 23, 1538-1544.	2.6	12
89	A Sensitivity Analysis of the Modified Chi-square Ratio Statistic for Equivalence Testing of Aerodynamic Particle Size Distribution. AAPS Journal, 2013, 15, 465-476.	4.4	12
90	iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes. Molecular Pharmaceutics, 2022, 19, 2040-2047.	4.6	12

#	Article	IF	Citations
91	Metabolism of dynorphin A1â€“13 in human CSF. Neurochemical Research, 1996, 21, 1213-1219.	3.3	11
92	In Vitro Performance Characteristics of Valved Holding Chamber and Spacer Devices with a Fluticasone Metered-Dose Inhaler. Pharmacotherapy, 2004, 24, 159-166.	2.6	11
93	Pulmonary targeting of sustained release formulation of budesonide in neonatal rats. Journal of Drug Targeting, 2006, 14, 680-686.	4.4	11
94	A selective LC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids. Journal of Pharmaceutical and Biomedical Analysis, 1991, 9, 761-767.	2.8	10
95	SPE/RIA vs LC/MS for measurement of low levels of budesonide in plasma. Biomedical Chromatography, 2003, 17, 14-20.	1.7	10
96	Pharmacokinetic and pharmacodynamic properties important for inhaled corticosteroids. Annals of Allergy, Asthma and Immunology, 2007, 98, S7-S15.	1.0	10
97	Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. Brain Research Bulletin, 2010, 81, 320-326.	3.0	10
98	Analysis of leucine enkephalin by high-performance liquid chromatography using enzymatic derivatization by tyrosinase and electrochemical or fluorescence detection. Journal of Pharmaceutical and Biomedical Analysis, 1999, 19, 855-864.	2.8	9
99	Simultaneous quantification of beclomethasone dipropionate and its metabolite, beclomethasone 17-monopropionate in rat and human plasma and different rat tissues by liquid chromatographyâ€“positive electrospray ionization tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 805, 203-210.	2.3	9
100	Simultaneous Determination of Dexamethasone, Dexamethasone 21â€Acetate, and Paclitaxel in a Simulated Biological Matrix by RPâ€HPLC: Assay Development and Validation. Journal of Liquid Chromatography and Related Technologies, 2008, 31, 1478-1491.	1.0	9
101	Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in Rats. Planta Medica, 2012, 78, 1831-1836.	1.3	9
102	Dose Optimization Based on Pharmacokinetic-Pharmacodynamic Modeling. , 2019, , 79-120.		9
103	A Selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomedical Chromatography, 1992, 6, 283-286.	1.7	8
104	Intranasal Loteprednol Etabonate in Healthy Male Subjects: Pharmacokinetics and Effects on Endogenous Cortisol. Journal of Clinical Pharmacology, 2004, 44, 510-519.	2.0	8
105	Systemic exposure to fluticasone MDI delivered through antistatic chambers. Journal of Allergy and Clinical Immunology, 2011, 128, 1113-1115.e3.	2.9	8
106	Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration. European Journal of Pharmaceutical Sciences, 2012, 45, 79-89.	4.0	8
107	Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales. Journal of Clinical Pharmacology, 2020, 60, 1051-1060.	2.0	8
108	A New Solution-Based Intranasal Triamcinolone Acetonide Formulation in Patients with Perennial Allergic Rhinitis: How Does the Pharmacokinetic/Pharmacodynamic Profile for Cortisol Suppression Compare with an Aqueous Suspension-Based Formulation?. Journal of Clinical Pharmacology, 2002, 42, 662-669.	2.0	7

#	Article	IF	Citations
109	Identification of Stabilized Dynorphin Derivatives for Suppressing Tolerance in Morphine-Dependent Rats. Pharmaceutical Research, 2004, 21, 1450-1456.	3.5	7
110	Application of the Modified Chi-Square Ratio Statistic in a Stepwise Procedure for Cascade Impactor Equivalence Testing. AAPS Journal, 2015, 17, 370-379.	4.4	7
111	An HPLC/RIA method for dynorphin A1-13 and its main metabolites in human blood. Journal of Pharmaceutical and Biomedical Analysis, 1997, 16, 101-109.	2.8	6
112	Assessment of complex peptide degradation pathways via structured multicompartmental modeling approaches: The metabolism of dynorphin A1â€“13 and related fragments in human plasma. Journal of Pharmaceutical Sciences, 1999, 88, 938-944.	3.3	6
113	Relative receptor affinity comparisons among inhaled/intranasal corticosteroids: perspectives on clinical relevance. Respiratory Research, 2008, 9, 75.	3.6	6
114	Optimization of the TranswellÂ® System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches. Pharmaceutics, 2021, 13, 1109.	4.5	6
115	[Biocytin13]dynorphin A 1-13 amide: a potential probe for the kappa-opioid receptor. Pharmaceutical Research, 1988, 05, 790-794.	3.5	5
116	Leucine enkephalin-tyrosinase reaction products â€" Identification and biological activity. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1222, 95-100.	4.1	5
117	Performance of a Corticosteroid Inhaler with a Spacer Fashioned from a Plastic Cold-Drink Bottle: Effects of Changing Bottle Volume. Journal of Asthma, 2003, 40, 237-242.	1.7	5
118	Quantitative characterization of circadian rhythm of pulmonary function in asthmatic patients treated with inhaled corticosteroids. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 391-399.	1.8	5
119	Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMAâ€™s Average Bioequivalence Approach. AAPS PharmSciTech, 2019, 20, 249.	3.3	5
120	A biotin-avidin-based enzyme immunoassay for beta h-endorphin. Pharmaceutical Research, 1988, 05, 232-235.	3.5	4
121	Fetal Concentrations of Budesonide and Fluticasone Propionate: a Study in Mice. AAPS Journal, 2019, 21, 53.	4.4	4
122	Quantitative Assessment of Pulmonary Targeting of Inhaled Corticosteroids Using Ex Vivo Receptor Binding Studies. AAPS Journal, 2020, 22, 39.	4.4	4
123	Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension. Pharmaceutical Research, 1990, 07, 558-560.	3.5	3
124	A new fluorogenic assay for tyrosine-containing peptides. Journal of Pharmaceutical and Biomedical Analysis, 1991, 9, 557-563.	2.8	3
125	Advances in single-entity inhaled corticosteroid therapy. Allergy and Asthma Proceedings, 2007, 28, 125-135.	2.2	3
126	Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristicsâ€. Journal of Pharmacy and Pharmacology, 2010, 59, 1473-1484.	2.4	3

#	Article	IF	Citations
127	Semi-mechanistic PK/PD model to assess pulmonary targeting of beclomethasone dipropionate and its active metabolite. European Journal of Pharmaceutical Sciences, 2021, 159, 105699.	4.0	3
128	Pharmacokinetics and pharmacodynamics of glycopyrrolate following a continuousâ€rate infusion in the horse. Journal of Veterinary Pharmacology and Therapeutics, 2014, 37, 133-144.	1.3	2
129	Effects of lipid formulations on clove extract spray dried powders: comparison of physicochemical properties, storage stability and in vitro intestinal permeation. Pharmaceutical Development and Technology, 2018, 23, 1047-1056.	2.4	2
130	Dissolution and drug release. , 2021, , 225-266.		2
131	Pharmacometrics in Pulmonary Diseases. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 349-382.	0.6	2
132	Pharmacokinetic Considerations in the Design of Pulmonary Drug Delivery Systems for Glucocorticoids. Drugs and the Pharmaceutical Sciences, 2001, , .	0.1	2
133	Workshop Report: USP Workshop on Advancements in In Vitro Performance Testing of Drug Products. Dissolution Technologies, 2020, 27, 52-70.	0.6	2
134	Response to the Commentary on â€œPharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogsâ€• Journal of Pharmaceutical Sciences, 1994, 83, 1067-1068.	3.3	1
135	A Novel Method for Polymer Coating of Plasmid DNA: Initial Investigations into the Use of Pulse Laser Deposition and Gene Delivery. Journal of Drug Targeting, 2004, 12, 237-241.	4.4	1
136	Pharmacokinetic and pharmacodynamic modeling of gut hormone peptide YY(3â€“36) after pulmonary delivery. Drug Development and Industrial Pharmacy, 2019, 45, 1101-1110.	2.0	1
137	Fluticasone furoate nasal spray in allergic rhinitis. Drugs of Today, 2008, 44, 251.	1.1	1
138	An avidinâ€”biotin based enzyme-linked immunosorbent assay for dynorphin A 1â€“13. Journal of Pharmaceutical and Biomedical Analysis, 1990, 8, 541-545.	2.8	0
139	PK/PD analysis of albuterol action: application to a comparative assessment of Î²2-adrenergic drugs. European Journal of Pharmaceutical Sciences, 1993, 1, 73-80.	4.0	0
140	P149 new electrochemical and fluoregenic assays for leucine enkephalin based on enzymatic derivatization by tyrosinase. European Journal of Pharmaceutical Sciences, 1994, 2, 156.	4.0	0
141	P140 a selective HPLC/RIA assay for budesonide in biological fluids. European Journal of Pharmaceutical Sciences, 1994, 2, 153.	4.0	0
142	P225 metabolism of DYN a 1â€“13 in human plasma. European Journal of Pharmaceutical Sciences, 1994, 2, 175.	4.0	0
143	Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in Rats. Planta Medica, 2013, 79, 312-312.	1.3	0
144	Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Detection and Quantification of Flunisolide in Tissue Culture Medium. Analytical Letters, 2013, 46, 1355-1363.	1.8	0

#	Article	IF	Citations
145	Evaluation of the Sensitivity and Robustness of Modified Chi-Square Ratio Statistic for Cascade Impactor Equivalence Testing Through Monte Carlo Simulations. AAPS PharmSciTech, 2020, 21, 147.	3.3	0
146	In Vitro Comparison of Fluticasone Respirable Dose From a Metered-Dose Inhaler and Three Ridged Valved Holding Chamber. Chest, 2003, 124, 137S.	0.8	0
147	Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers. AAPS Journal, 2022, 24, 9.	4.4	0